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A 64-year-old asymptomatic patient was ad-
mitted to the hospital due to high gradients of 
the biological aortic valve, which was diagnosed 
during a control transthoracic echocardiographic 
examination. The patient suffered from aortic 
valve regurgitation as a complication of infective 
endocarditis and he underwent aortic valve replace-
ment with bioprosthesis 15 months before admis-
sion. Warfarin was started after cardiac surgery 
and was continued for 3 months. The therapy was 
then withdrawn and switched to acetylsalicylic 
acid (ASA). The highest systolic gradients of aor-
tic bioprosthesis from echocardiographic reports 
during the first 6 months after surgery were 
35/22 mm Hg (maximum/mean systolic gradi-
ent). During hospitalization a transthoracic and 
transesophageal examinations were performed, 
which confirmed high systolic gradients (68.3/ 
/46.5 mm Hg; Fig. 1). The calculated effective valve 
area was 1.0 cm2. Due to dissatisfactory visualiza-
tion of bioprosthesis leaflets on the echocardiog-
raphy, the patient was referred to have cardiac 
multidetector computed tomography (MDCT). 
The MDCT showed that the basal part of the aortic 
bioprosthesis leaflets was thickened with limited 
mobility. Antithrombotic treatment with low-mo-
lecular-weight heparin was commenced, and after 
10 days a slight decrease of gradient was observed 
(48.9/30.3 mm Hg). The patient was then switched 
to warfarin and discharged from the hospital. The 
aortic gradient decreased to 23.6/13.9 mm Hg after 
3 months of treatment. The calculated affective 
valve area after treatment was 1.4 cm2. During 
a control cardiac MDCT we observed a resolution 
of thrombotic changes with normal leaflet mobility 
and normal leaflet thickness.
Recently, Makkar et al. [1] reported an in-
creased prevalence of bioprosthetic aortic valves 
thrombosis on MDCT examination. According to 
the authors, multiple bioprosthesis types were af-
fected including the ones with transcatheter (TAVR) 
and surgically (AVR) implanted bioprostheses. The 
authors’ preliminary report included patients from 
ongoing RESOLVE and SAVORY registries, as well 
as a PORTICO IDE randomized trial, which were 
started to establish the effect of this finding on 
clinical outcomes [2–4]. Affected patients appeared 
to be hemodynamically subclinical at the time of 
detection, with normal aortic valve gradients on 
their echocardiography. The median time to MDCT 
examination was significantly shorter after the 
AVR/TAVR procedure in comparison to our patient, 
who was asymptomatic but he had significantly 
increased aortic bioprosthesis gradients. It is pos-
sible that the valve thrombosis that we observed 
was more severe due to the longer period of time 
after valve replacement. According to the European 
Society of Cardiology guidelines anticoagulant 
therapy has been challenged in patients with aortic 
bioprosthesis, with the use of low-dose ASA now 
favoured as an alternative. Further randomized tri-
als are needed to establish the clinical significance 
of the finding of Makkar et al. [1], but possibly 
biological valve thrombosis and its consequences 
due to insufficient antithrombotic treatment occur 
more frequently than had been previously assumed.
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Figure 1. A, B. Multidetector computed tomography (MDCT) multiplanar reconstruction demonstrating thrombosed 
aortic bioprosthesis before antithrombotic treatment (arrowheads); C. Transthoracic echocardiography, continuous 
spectral Doppler imaging, and high aortic bioprosthesis systolic gradient before antithrombotic treatment; D, E. MDCT 
after treatment; F. Transthoracic echocardiography, decreased gradient after treatment.
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